News stories about Thermo Fisher Scientific (NYSE:TMO) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Thermo Fisher Scientific earned a daily sentiment score of 0.17 on Accern’s scale. Accern also gave news headlines about the medical research company an impact score of 47.0636674762175 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:

A number of equities analysts have recently issued reports on the stock. Jefferies Group restated a “hold” rating and issued a $195.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, September 28th. Goldman Sachs Group assumed coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, September 26th. They issued a “buy” rating and a $225.00 price objective for the company. Barclays restated an “overweight” rating and issued a $215.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Monday, September 25th. Leerink Swann restated an “outperform” rating and issued a $200.00 price objective (down previously from $216.00) on shares of Thermo Fisher Scientific in a research note on Monday, December 4th. Finally, Argus restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, August 22nd. They noted that the move was a valuation call. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $205.21.

Shares of Thermo Fisher Scientific (NYSE:TMO) traded up $2.33 during trading on Friday, hitting $187.96. 2,429,212 shares of the company were exchanged, compared to its average volume of 1,666,042. The firm has a market cap of $75,371.02, a PE ratio of 20.65, a P/E/G ratio of 1.72 and a beta of 1.06. The company has a quick ratio of 0.81, a current ratio of 1.26 and a debt-to-equity ratio of 0.85. Thermo Fisher Scientific has a 1-year low of $139.88 and a 1-year high of $201.20.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.24 by $0.07. The business had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $5.03 billion. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The firm’s revenue for the quarter was up 13.9% on a year-over-year basis. During the same quarter last year, the company posted $2.03 EPS. equities analysts predict that Thermo Fisher Scientific will post 9.36 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be given a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.32%. The ex-dividend date of this dividend is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.19%.

In related news, CEO Marc N. Casper sold 50,000 shares of the stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the completion of the sale, the chief executive officer now owns 252,577 shares in the company, valued at approximately $47,582,981.03. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.49% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Thermo Fisher Scientific (TMO) Stock Price” was published by Watch List News and is the property of of Watch List News. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Insider Buying and Selling by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.